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INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac arrhythmia, 
occurring in 1–2% of the general population.1,2 AF confers a 
five-fold risk of stroke, and one in five of all strokes is attributed 
to this arrhythmia.3 Therefore, the administration of antithrom-
botic (antiplatelet or anticoagulant) medication is critical for 
the prevention of thromboembolic events in patients with AF. 
According to recent worldwide data, the number of patients 
taking antithrombotic medication is expected to rise with an 
increase in the number of AF patients.4 Although major bleed-
ing, including intracranial hemorrhage or gastrointestinal bleed-
ing, has been evaluated intensively, minor bleeding events (nui-
sance bleedings), including ocular bleeding, have not been well 
Antithrombotic Medication and the Risk of Vitreous 
Hemorrhage in Atrial Fibrillation: Korean National 
Health Insurance Service National Cohort 
Ko Eun Kim1*, Pil-Sung Yang2*, Eunsun Jang3, Sungjin Kim1, and Boyoung Joung3
1Department of Ophthalmology, Nowon Eulji Medical Center, Eulji University, Seoul;
2Department of Cardiology, CHA Bundang Medical Center, CHA University, Seongnam;
3Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea.
Purpose: Antithrombotic therapy could be related with nuisance bleeding. This study investigated whether vitreous hemorrhage 
(VH) is associated with specific types of antithrombotic medication in patients with atrial fibrillation (AF). 
Materials and Methods: In the Korean National Health Insurance Service National Sample Cohort, we identified 9352 antiplatelet/
anticoagulant-treated AF patients. The occurrence of VH was compared between warfarin (n=1493) and a propensity score (PS)-
matched antiplatelet group (n=1493) and between warfarin (n=1493) and a PS-matched warfarin+antiplatelet group (n=1493).  
Results: The outcomes of VH were lower in the warfarin than in the matched antiplatelet (1.45 vs. 3.72 events/1000 patient-years) 
and matched warfarin+antiplatelet groups (1.45 vs. 6.87 events/1000 patient-years). Compared with warfarin, the risk of VH in-
creased with antiplatelet [adjusted hazard ratio (aHR) 3.90; 95% confidence interval (CI) 1.22–12.4, p=0.022] and warfarin+antiplatelet 
agents (aHR 4.39, 95% CI 1.74–11.2, p=0.002). Compared with warfarin only, warfarin+antiplatelet agents increased the risk of VH 
in patients ≥65 years, regardless of gender and hypertension. The risk of VH was significantly higher with dual antiplatelet therapy 
(aHR: 5.02, 95% CI: 1.56–16.2, p=0.007) or in dual (aHR: 5.02, 95% CI: 1.74–14.5, p=0.003) or triple therapy using warfarin and anti-
platelet agents than with warfarin monotherapy (aHR: 6.12, 95% CI: 1.76–21.3, p=0.004). 
Conclusion: Dual antiplatelet or triple therapy increased the risk of VH significantly, compared to warfarin monotherapy. Consider-
ing the low efficacy of preventing ischemic stroke and high risk of bleeding, dual or triple therapy using warfarin and antiplatelet 
agents should be avoided to prevent VH in AF patients.
Key Words:  Vitreous hemorrhage, antiplatelet, anticoagulant, atrial fibrillation
Original Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Received: September 20, 2018   Revised: November 2, 2018
Accepted: November 19, 2018
Co-corresponding authors: Boyoung Joung, MD, PhD, Division of Cardiology, 
Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seo-
daemun-gu, Seoul 03722, Korea.
Tel: 82-2-2228-8460, Fax: 82-2-393-2041, E-mail: cby6908@yuhs.ac and
Sungjin Kim, MD, PhD, Department of Ophthalmology, Nowon Eulji Medical Cen-
ter, Eulji Univeristy, 68 Hangeulbiseok-ro, Nowon-gu, Seoul 01830, Korea.
Tel: 82-2-970-8322, Fax: 82-2-970-8003, E-mail: ksj4107@eulji.ac.kr
*Ko Eun Kim and Pil-Sung Yang contributed equally to this work.
•The authors have no potential conflicts of interest to disclose.
© Copyright: Yonsei University College of Medicine 2019
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (https://creativecommons.org/licenses/
by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Yonsei Med J 2019 Jan;60(1):65-72
https://doi.org/10.3349/ymj.2019.60.1.65
66
Vitreous Hemorrhage in Atrial Fibrillation
https://doi.org/10.3349/ymj.2019.60.1.65
investigated. Recently, however, the importance of surveillance 
and adequate management for nuisance hemorrhagic compli-
cations arising from using these medications has been high-
lighted.5 Nuisance bleedings is common among patients with 
AF on oral anticoagulants (OACs). However, nuisance bleed-
ings was not associated with a higher risk of major bleeding or 
stroke/systemic embolism over the next 6 months, suggesting 
its occurrence should not lead to changes in anticoagulation 
treatment strategies.
Vitreous hemorrhage (VH) is a potential intraocular hemor-
rhagic complication associated with oral antiplatelet or anti-
coagulant medication, such as aspirin, clopidogrel bisulfate, 
and warfarin sodium.6-12 Although VH can be absorbed sponta-
neously, it can also result in more serious complications threat-
ening vision, such as intraocular pressure increase and prolifer-
ative vitreoretinopathy, leading to invasive surgical intervention. 
Moreover, many AF patients discontinue antiplatelet or anti-
coagulant medication after VH and might experience throm-
boembolic events during this period. Therefore, the associa-
tion between VH and antiplatelet or anticoagulant medication 
is important for both ophthalmologists and cardiologists.
Previous clinical studies have reported varying degrees of 
associations between VH and oral antiplatelet or anticoagulant 
use.6-12 However, most studies were performed on populations 
with specific retinal diseases or patients undergoing intraocu-
lar interventions. Epidemiological data are limited for general-
izing the impact of antiplatelet or anticoagulation medication 
on VH risk. In this regard, we investigated the effects of anti-
platelet and anticoagulation medication on VH development 
and non-pharmacological risk factors of VH in patients with AF 
using the Korean National Health Insurance Service (NHIS) 
database.
MATERIALS AND METHODS
Data source
This study was conducted using the NHIS-National Sample Co-
hort (NSC).13 The NHIS database represents the nationwide 
population of South Korea.1-3 The NHIS is a single insurer man-
aged by the Korean government that covers 97% of the entire 
population; other programs, such the Medical Assistance Pro-
gram, cover the remaining 3%. The National Health Insurance 
Claim database stores data on the entire Korean population, 
including all demographic and medical information. Based on 
this database, the NHIS-NSC was created and released in 2014.13 
It contains medical claims for 2.2% (n=1025340) of the total 
Korean population (about 50 million); individuals were ran-
domly selected from January 1, 2002. NHIS-NSC data provide 
information on healthcare utilization based on the National 
Health Insurance claims from medical institutions to the NHIS 
for inpatient and outpatient clinic visits.1-3 The database is open 
to researchers once their study protocol has been approved by 
an official review committee. The Institutional Review Board of 
Severance Hospital at Yonsei University College of Medicine 
approved our study (4-2014-0996). Since we used anonymous 
data, the requirement to obtain informed consent was waived. 
Study population
The current study included patients aged 19 years or older who 
were diagnosed with AF from January 2002 to December 2008. 
Patients with AF were identified using the International Clas-
sification of Disease, Tenth Revision (ICD-10): I480, I481, I482, 
I484, and I489. AF was validated in previous studies with a posi-
tive predictive value of 94.1%.1-3 To ensure diagnostic accuracy, 
we defined patients with AF only when they had a discharge di-
agnosis or were confirmed more than twice in the outpatient 
department.1-3 We excluded patients without a history of anti-
platelet/anticoagulant use before enrollment. Among 9352 pa-
tients who were followed from January 2009 to December 2013, 
we identified 6074 antiplatelet agent-treated patients, 1493 war-
farin-treated patients, and 1785 warfarin+antiplatelet agent-
treated patients. The occurrence of VH was compared between 
warfarin (n=1493) and a 1:1 propensity score (PS)-matched an-
tiplatelet group (n=1493) and between warfarin (n=1493) and a 
1:1 PS-matched warfarin+antiplatelet group (n=1493) (Fig. 1). 
We obtained information on selected comorbid conditions 
from inpatient and outpatient hospital diagnoses. Baseline 
comorbidities were defined using the medical claims and pre-
scription medication prior to the index date. In order to ensure 
diagnostic accuracy, patients were considered to have comor-
bidities when the condition was a discharge diagnosis or was 
Fig. 1. Study cohort. NHIS-NSC, National Health Insurance Service-Na-
tional Sample Cohort. AF, atrial fibrillation; PS, propensity score.
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confirmed at least twice in an outpatient setting, which was 
similar to previous studies with NHIS (Supplementary Table 1, 
only online).14-17 Also CHA2DS2-VASc [congestive heart failure, 
hypertension, age ≥75 (doubled), diabetes mellitus, prior 
stroke or transient ischemic attack (TIA) (doubled), vascular 
disease, age 65 to 74, female] score and HAS-BLED [hyperten-
sion, abnormal renal/liver function (1 point each), stroke, bleed-
ing history, labile INR (left out because of data are unavailable), 
elderly (>65 years), concomitant drug (1 point each)] score 
were evaluated.1
Exposure of antiplatelet and anticoagulation agents
The exposure to antiplatelet and anticoagulation agents was 
identified based on filled antiplatelet or anticoagulant medi-
cation prescriptions over the follow-up period between January 
2009 and December 2013. We used the most common medi-
cations for stroke prevention in patients with AF: aspirin and 
P2Y12 inhibitors (clopidogrel bisulfate, prasugrel, and ticagre-
lor) for antiplatelet medication and warfarin sodium for anti-
coagulation medication. The index date was defined as the date 
of first prescription of antiplatelet, warfarin, and warfarin + an-
tiplatelet agents in antiplatelet, warfarin, and warfarin + anti-
platelet groups, respectively.
Study outcome
The study outcome was newly developed VH (ICD-10 code 
H43.1) during the follow-up period between 2009 and 2013. To 
evaluate the accuracy of our definition of VH, we conducted a 
validation study with 102 randomly chosen patients with the 
ICD-10 code H43.1. Fundus photos and ultrasonographic im-
ages were reviewed by two ophthalmologists (KEK and SJK). 
The patients were deemed to have VH if it was documented by 
fundus photos and ultrasonography examinations. The posi-
tive predictive value was 95.3%. To ensure diagnostic accuracy, 
we defined patients with VH only when they had a discharge 
diagnosis or were confirmed more than twice in the outpatient 
department. The follow-up period was defined as from the in-
dex date until the first occurrence of VH or the end date of the 
study period, whichever came first. 
Statistical analysis
The PS method, which simulates the effect of a randomized 
clinical trial for observational cohort data, was used to study 
the effects of warfarin on the occurrence of VH in comparison 
to other groups. PS reflects the predicted probability of treat-
ment conditional on selected covariates, including age, sex, 
baseline comorbidities, and CHA2DS2-VASc and HAS-BELD 
scores, using logistic regression. The balance of covariates at 
baseline among the study groups was assessed using the ab-
solute standardized mean difference (SMD). An absolute SMD 
<0.1 indicates a negligible difference in potential confounders 
between two study groups.
Incidence rates were estimated using the total number of 
study outcomes during the follow-up period divided by person-
years at risk. The 95% confidence interval (CI) of incidence 
rate was estimated using a Poisson distribution.18 The risk of 
VH for warfarin versus other drugs was obtained using survival 
analysis: Kaplan-Meier method and log-rank test for univari-
ate analysis and Cox proportional hazards regression for mul-
tivariate analysis. We adjusted for age, gender, heart failure, 
hypertension, diabetes, stroke/TIA, previous myocardial in-
farction, dyslipidemia, hemorrhagic stroke, valvular heart disease, 
malignancy, nonsteroidal anti-inflammatory drugs (NSAID), 
and corticosteroid medications. Statistical analyses were per-
formed using Statistical Package for the Social Science version 
19.0 for Windows (IBM Corp., Armonk, NY, USA) and MedCalc 
(v. 12.0; MedCalc Statistical software, Marakierke, Belgium). 
Statistical significance was defined as p<0.05.
RESULTS
Study subjects
Before PS matching, the warfarin group was younger, had lower 
CHA2DS2-VASc score, and had a lower proportion of comor-
bidities than other groups (Supplementary Table 2, only online). 
After PS matching, both of the two groups were well balanced 
with the warfarin group for all characteristics (all SMD <0.1). The 
warfarin group included more patients with valvular heart 
disease, including mitral stenosis or prosthetic mitral valve, 
than the other groups (20.4, 1.1, and 7.0%, p<0.001) (Table 1). 
 
Primary study outcomes
The cumulative incidence of VH is shown in Fig. 2. Overall, cu-
mulative incidence curves revealed a lower rate of VH with war-
farin than in matched antiplatelet (log rank p=0.003) (Fig. 2A) 
or warfarin+antiplatelet groups (log rank p<0.001) (Fig. 2B). 
The cumulative incidence of VH in each group is shown in Sup-
plementary Fig. 1 (only online).
The outcomes of VH were lower for warfarin than for matched 
antiplatelet (1.45 vs. 3.72 events/1000 patient-years) and matched 
warfarin+antiplatelet groups (1.45 vs. 6.87 events/1000 pa-
tient-years). Compared with warfarin, the risk of VH was in-
creased with antiplatelet [adjusted hazard ratio (aHR) 3.90; 
95% CI 1.22–12.4, p=0.022] and warfarin+antiplatelet agents 
(aHR 4.39, 95% CI 1.74–11.2, p=0.002) (Table 2). 
Similar findings were observed in a sensitivity analysis that 
compared rates of VH after excluding patients with valvular 
heart disease. In sensitivity analysis, the outcomes of VH were 
lower in the warfarin than in the matched antiplatelet (1.79 vs. 
5.33 events/1000 patient-years) and matched warfarin + anti-
platelet groups (1.79 vs. 7.21 events/1000 patient-years). The risk 
of VH was lower for warfarin than for antiplatelet (aHR 4.64, 
95% CI 1.38–15.5, p=0.013) and warfarin+antiplatelet groups 
(aHR 4.15, 95% CI 1.57–11.0, p=0.004) (Table 3). 
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Outcomes according to different medications
Compared with warfarin, the risk of VH was significantly higher 
in dual antiplatelet therapy using aspirin and P2Y2 inhibitor 
(1.45 vs. 8.70 events/1000 patient-years; aHR: 5.02, 95% CI: 
1.56–16.2, p=0.007), dual therapy using warfarin and aspirin 
(1.45 vs. 6.82 events/1000 patient-years; aHR: 5.02, 95% CI: 
1.74–14.5, p=0.003), and also triple therapy using warfarin, as-
pirin, and P2Y2 inhibitor (1.45 vs. 8.91 events/1000 patient-
years; aHR: 6.12, 95% CI: 1.76–21.3, p=0.004). However, P2Y2 
inhibitor monotherapy or dual therapy using warfarin and 
P2Y2 inhibitors did not increase the risk of VH (Fig. 3). 
Supplementary Fig. 2 (only online) shows the risk of VH ac-
Table 1. Characteristics of Warfarin and Propensity Score-Matched Antiplatelet or Warfarin+Antiplatelet-Treated Patients with Atrial Fibrillation
 
Warfarin
(n=1493)
Antiplatelet
(n=1493)
Warfarin+antiplatelet
(n=1493)
SMD
(warfarin vs.  
antiplatelet)
SMD
(warfarin vs. warfarin+ 
antiplatelet)
Age (yr) 67 (56, 73) 66 (56, 74) 67 (57, 74) -0.020 -0.098
Men 782 (52.4) 798 (53.4) 829 (55.5) 0.022 0.063
Congestive heart failure 559 (37.4) 539 (36.1) 516 (34.6) 0.028 0.060
Hypertension 1087 (72.8) 1057 (70.8) 1141 (76.4) 0.045 -0.081
Diabetes mellitus 231 (15.5) 228 (15.3) 289 (19.4) 0.006 -0.097
Ischemic stroke or TIA 333 (23.1) 356 (23.8) 345 (23.1) 0.019 -0.018
Previous MI 113 (7.6) 129 (8.6) 113 (9.8) 0.035 -0.041
PAD 104 (7.0) 104 (7.0) 131 (8.8) 0.049 -0.077
Dyslipidemia 639 (42.8) 626 (41.9) 717 (48.0) 0.018 -0.096
Hemorrhagic stroke 23 (1.5) 14 (0.9) 27 (1.8) 0.049 -0.022
Malignancy 233 (15.6) 215 (14.4) 238 (15.9) 0.032 -0.009
CHA2DS2-VASc score 3.00 (2.00, 4.00) 3.0 (1.0, 4.0) 3.0 (2.0, 5.0) 0.032 -0.067
HAS-BLED score 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 3.0 (2.0, 3.0)  0.011  -0.091
Propensity score-unmatched variables
Valvular heart disease 305 (20.4) 16 (1.1) 104 (7.0)
NSAID 586 (39.2) 721 (48.3) 676 (45.3)
Steroid 122 (8.2) 148 (9.9) 154 (10.3)
CHA2DS2-VASc, congestive heart failure, hypertension, age of ≥75 years (doubled), diabetes mellitus, prior stroke or TIA (doubled), vascular disease, age of 65 
to 74 years, female sex; HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history, labile INR (left out because of data are 
unavailable), elderly (>65 years), concomitant drug (1 point each); MI, myocardial infarction; NSAID, nonsteroidal anti-inflammatory drugs; PAD, peripheral artery 
disease; TIA, transient ischemic attack; SMD, standardized mean difference.
Values are presented as numbers (%) or medians (interquartile range). 
Fig. 2. Cumulative incidence of vitreous hemorrhage (VH). (A) Warfarin vs. antiplatelet agents. (B) Warfarin vs. warfarin+antiplatelet agents.
0.20
0.15
0.10
0.05
0.00
0.20
0.15
0.10
0.05
0.00
0                1              2               3              4                5 0                1              2               3              4                5
Years Years
Number at risk
A 1493 947 701 495 326 76
W 1493 1090 927 774 633 363
Number at risk
W+A 1493 841 464 269 182 86
W 1493 1090 927 774 633 363
Cu
m
ul
at
ive
 in
cid
en
ce
 o
f V
H
Cu
m
ul
at
ive
 in
cid
en
ce
 o
f V
H
p=0.003 p<0.001
Antiplatelet agents (A)
Warfarin (W)
Warfarin+antiplatelet agents (W+A)
Warfarin (W)
A B
69
Ko Eun Kim, et al.
https://doi.org/10.3349/ymj.2019.60.1.65
VH
No. of patients No. of events /1000 PYs (95% CI)
Adjusted HR
(95% CI)
p value
Warfarin (W) 1493 7 1.45 (0.63–2.86) 1 -
Aspirin (A) 994 5 2.25 (0.82–4.99) 1.68 (0.47–6.07) 0.427
P2Y2 (C) 140 0 - - -
A+C 359 7 8.70 (3.52–18.1) 5.02 (1.56–16.2) 0.007
W+A 1007 11 6.82 (3.59–11.9) 5.02 (1.74–14.5) 0.003
W+C 161 1 3.16 (0.16–15.6) 1.99 (0.19–21.2) 0.569
W+A+C 325 6 8.91 (3.90–17.6) 6.12 (1.76–21.3) 0.004
cording to warfarin, antiplatelet agents, and warfarin + antiplate-
let agents in overall patients.
Outcomes by different subgroups 
Compared with warfarin, antiplatelet agents significantly in-
creased the risk of VH in patients with hypertension and stroke 
or TIA (Fig. 4A). The risk of VH was generally increased by 
warfarin+antiplatelet agents across most subgroups, except 
younger age, diabetes, heart failure, and previous history of 
stroke or TIA. The risk of VH was increased in patients equal 
or older than 65 years, but not in those younger than 65 years 
(Fig. 4B).
Compared with warfarin, the risk of VH was generally in-
creased by dual antiplatelet agents, dual therapy warfarin and 
P2Y2 inhibitor, and triple therapy with warfarin, aspirin and 
P2Y2 inhibitor (Supplementary Fig. 3, only online).
 
 DISCUSSION
The main findings of this study are a lower incidence of VH for 
warfarin than for antiplatelet or warfarin+antiplatelet treated 
individuals. Compared with warfarin, the risk of VH was in-
creased with antiplatelet and warfarin+antiplatelet agents by 
3.9 and 4.39 times, respectively. Second, compared with war-
farin monotherapy, warfarin+antiplatelet agents increased 
the risk of VH in patients equal or more than 65 years, but not 
in those younger than 65 years. Finally, while combination 
treatment including aspirin (dual antiplatelet therapy, dual or 
Table 2. Cox Proportional HR of the Risk of Different Types of Antiplatelet and Anticoagulant Medications for Vitreous Hemorrhage in Patients with 
Atrial Fibrillation
Warfarin (n=1493) Antiplatelet agents (n=1493) Warfarin+antiplatelet agents (n=1493)
Events 7 12 18
Person years 4844 3230 2619
/1000 PYs (95% CI) 1.45 (0.63–2.86) 3.72 (2.01–6.32) 6.87 (4.20–10.7)
HR (95% CI), p value
Unadjusted 1 (Reference) 5.11 (1.59–16.4), 0.002 5.19 (2.11–12.7), <0.001
Clinical variable-adjusted* 1 (Reference) 3.90 (1.22–12.4), 0.022 4.39 (1.74–11.2), 0.002
CI, confidence interval; HR, hazard ratio; PYs, person years.
*Adjusted by age, gender, heart failure, hypertension, diabetes, stroke/transient ischemic attack, previous myocardial infarction, dyslipidemia, hemorrhagic 
stroke, valvular heart disease, malignancy, nonsteroidal anti-inflammatory drugs and corticosteroid medications.
Table 3. Cox Proportional HR of the Risk of Different Types of Antiplatelet and Anticoagulant Medications for Vitreous Hemorrhage in Patients with 
Non-Valvular Atrial Fibrillation
Warfarin (n=1188) Antiplatelet agents (n=1474) Warfarin+antiplatelet agents (n=1389)
Events 6 17 17
Person years 3355 3192 2357
/1000 PYs (95% CI) 1.79 (0.72–3.72) 5.33 (3.20–8.35) 7.21 (4.34–11.31)
HR (95% CI), p value
Unadjusted 1 (Reference) 4.58 (1.37–15.3), 0.013 4.17 (1.62–10.8), 0.003
Clinical variable-adjusted* 1 (Reference) 4.64 (1.38–15.5), 0.013 4.15 (1.57–11.0), 0.004
CI, confidence interval; HR, hazard ratio; PYs, person years.
*Adjusted by age, gender, heart failure, hypertension, diabetes, stroke/transient ischemic attack, previous myocardial infarction, dyslipidemia, hemorrhagic 
stroke, valvular heart disease, malignancy, nonsteroidal anti-inflammatory drugs and corticosteroid medications.
Fig. 3. Risk of VH according to different warfarin or antiplatelet agent combinations. VH, vitreous hemorrhage; CI, confidence interval; HR, hazard ratio.
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        Warfarin+antiplatelet agents Adjusted HR (95% CI) p value
Male 3.93 (1.15–13.3) 0.028
Female 7.06 (1.58–35.1) 0.017
<65 yrs 1.21 (0.32–4.57) 0.779
≥65 yrs 18.5 (3.50–97.7) 0.001
HTN No 21.7 (1.24–382) 0.040
 Yes 3.90 (1.38–11.0) 0.010
DM No 5.52 (1.44–21.2) 0.013
 Yes 3.08 (0.73–12.8) 0.123
HF      No 7.23 (1.97–26.5) 0.003
 Yes 2.14 (0.47–9.72) 0.325
Stroke/TIA  No 4.94 (1.48–16.5) 0.009
 Yes 3.19 (0.64–15.9) 0.157
      Antiplatelet agents Adjusted HR (95% CI) p value
Male 4.06 (0.98–16.8) 0.053
Female 3.15 (0.51–19.4) 0.214
<65 yrs 2.19 (0.61–7.85) 0.139
≥65 yrs 1E12 (0–1E32) 0.237
HTN No 2.83 (0.09–86.5) 0.552
 Yes 4.85 (1.35–17.5) 0.016
DM No 3.35 (0.58–19.5) 0.179
 Yes 4.21 (0.80–22.2) 0.090
HF No 3.78 (0.77–18.4) 0.099
 Yes 6.51 (0.95–44.6) 0.057
Stroke/TIA No 2.86 (0.69–11.9) 0.147
 Yes 12.8 (1.24–130) 0.032
triple therapy using warfarin and antiplatelet agents) in-
creased the risk of VH, that without aspirin (dual therapy us-
ing warfarin and P2Y2 inhibitors) did not significantly increase 
the risk of VH. This finding suggests that a combination of an-
tiplatelet and anticoagulation agents should be avoided, espe-
cially in older adult patients, and cautiously recommends the 
use of P2Y2 inhibitor instead of aspirin if combination therapy 
is needed.
Stroke prevention is the principal management priority in 
patients with AF. Compared to control or placebo, OAC therapy 
reduces the risk of stroke by 64% and the risk of death by 26%,19 
but also increases bleeding risk, which can be fatal. Despite 
the positive net clinical benefit of OACs in the majority of pa-
tients with AF, between 30% and 50% of patients meeting indi-
cations for OACs with AF are not on treatment.20 The OAC rate 
of total AF in the Korean nationwide cohort remains very low 
at about 18%, while the usage rate of aspirin exceeds 35%.4,14 
The analysis of a prospective multicenter study performed in 
tertiary hospitals in Korea [COmparison study of Drugs for 
symptom control and complication prEvention of Atrial Fibril-
lation (CODE-AF) registry] showed the optimistic future of 
stroke prevention in patients with AF. The current OAC rate of 
AF patients with high stroke risk (CHA2DS2-VASc score ≥2) 
was about 83%.21 Bleeding risk is commonly cited as a reason 
for stopping OAC therapy in high-risk patients.22,23 
Nuisance bleeding events (e.g., bruising, epistaxis, intraocu-
lar bleeding) are substantially more common than more seri-
ous adverse bleeding events.24 As an indicator of bleeding ten-
dency, they may influence decisions regarding discontinuation 
of OAC therapy, especially in older patients.25 Although it is 
considered a type of nuisance bleeding, intraocular hemor-
rhage is important and can lead to vision-threatening situa-
tions. The incidence of VH was reported as seven cases per 
100000 person-years in the general population.26 However, 
the incidence of VH in AF patients with antithrombotic medi-
cations has not been well identified. While some studies have 
reported that antiplatelet or anticoagulation medication in-
creases the possibility of intraocular hemorrhage,6-8 others 
Fig. 4. Subpopulation analysis in patients with diverse comorbidities. The point estimates of vitreous hemorrhage risk in group with antiplatelet (A) or 
warfarin+antiplatelet combination (B) compared with reference (warfarin). HTN, hypertension; DM, diabetes mellitus; HF, heart failure; TIA, transient isch-
emic attack; HR, hazard ratio; CI, confidence interval.
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had contrary findings.9-12,27 In this study, while the incidence 
of VH was 1.45 cases per 1000 person-years in warfarin mono-
therapy, it increased to 8.91 cases per 1000 person-years by tri-
ple therapy. Dual antiplatelet therapy and dual therapy with as-
pirin and P2Y2 inhibitors significantly increased the risk of 
VH more than warfarin monotherapy. More importantly, aspi-
rin monotherapy had an incidence of VH of 2.25 cases per 1000 
person-years with the same bleeding risk as warfarin mono-
therapy. Therefore, considering the low efficacy of aspirin to 
prevent stroke and similar risk of bleeding, aspirin should be 
avoided in AF patients. However, the use of aspirin for stroke pre-
vention in AF patients is more than 30% in Korean AF patients.14 
Theoretically, triple therapy combining all drugs, including 
dual antiplatelet therapy and warfarin, may be a reasonable 
choice as an initial antithrombotic regimen. However, prolonged 
triple therapy has been shown to be associated with an increased 
risk of bleeding and even mortality.28,29 Recent well-designed 
RCTs suggested dual therapy with a single antiplatelet agent 
and an OAC might be safer and show similar efficacy to triple 
therapy for preventing ischemic/thromboembolic events.28,30-32 
Dual therapy with clopidogrel and OAC was suggested to be a 
safe initial alternative regimen to triple therapy.30,31 Consistent-
ly, this study showed that dual therapy with warfarin and P2Y2 
inhibitor did not significantly increase the risk of VH.
Witmer and Cohen7 reported that patients taking aspirin, 
clopidogrel, or warfarin who developed acute posterior vitreous 
detachment were more likely to present with VH. Their results 
showed that the number of eyes with VH was significantly larg-
er in patients taking antithrombotic medications than in those 
not taking them (43% vs. 31%, p=0.034). Interestingly, P2Y2 in-
hibitors monotherapy or dual therapy using warfarin and 
P2Y2 inhibitors did not increase the risk of VH significantly. 
Our study also showed that triple therapy increased the risk 
of VH in older adults equal or older than 65 years, but not in 
those younger than 65 years. Consistently, Biyik, et al.8 report-
ed that warfarin increased the frequency of ocular bleeding in 
patients with hypertension and older age. In patients who were 
diagnosed as neovascular age-related macular degeneration 
(AMD), arterial hypertension was a strong risk factor for large 
subretinal hemorrhages,33 and antiplatelet or anticoagulant 
use was significantly associated with retinal or subretinal hem-
orrhage only in patients with hypertension.34 Previously, a sig-
nificant association was reported between diabetes and hy-
pertension with macular hemorrhage (including VH) after 
intravitreal injection for neovascular AMD.35 Consistently, our 
findings suggest the importance of cautious monitoring for 
VH risk in patients with AF on stroke prevention therapy with 
such clinical characteristics.
Several limitations should be considered when interpreting 
our results. First, since the present study was a retrospective 
study using NHIS-NSC database, it had the intrinsic limita-
tions as a retrospective study. Second, we tried to determine the 
incidence of spontaneous VH from antithrombotic medication; 
however, the ICD-10 code was not specialized to spontaneous 
VH. It is possible that the incidence of VH is underestimated in 
patients who take anti-platelets/anti-coagulants based on da-
tabase records, since the clinicians did not mention it in the 
medical record. However, because VH is a serious disease re-
lated with blindness, the possibility of underestimation is rela-
tively low. Third, because the reason of discontinuation of an-
ti-platelets/anti-coagulants was not available in the database, 
we could not present the number of patients who stopped tak-
ing anti-platelets/anti-coagulants due to VH. Finally, although 
we used PS matching among groups, uncontrolled covariates 
may exist. Despite these limitations, the strength of this study 
is that it included a large, population-based dataset to deter-
mine whether VH and the most commonly used antiplatelet 
and anticoagulation medications were associated.
In conclusion, dual antiplatelet or triple therapy including 
aspirin appears to increase the risk of VH, compared to warfa-
rin monotherapy. This finding suggests that a combination of 
antiplatelet and anticoagulation agents should be avoided, 
especially in elderly patients, and recommends the use of P2Y2 
inhibitor instead of aspirin if combination therapy is needed.
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